[Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
D000368:Aged; D001593:Benzyl Compounds / Q000008:administration & dosage; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D012694:Serine / Q000008:administration & dosage*; D013064:Speech Disorders / Q000188:drug therapy; D014202:Tremor / Q000188:drug therapy
D001593:Benzyl Compounds; D006834:Hydrazines; D012694:Serine; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases
Klinische Beobachtungen über die Kombinationsbehandlung des Parkinson-Syndroms mit L-Dopa und dem Dekarboxylasehemmer Ro 4-4602.